KRAS and neoplasm: It has therefore become critical to further elucidate the moleculardeterminants that underpin the interaction between the tumour and the immune system.Increasing evidence suggests that tumour-cell-intrinsic oncogenic signalling,including KRAS signalling (6), can hamperanti-tumour immune responses and there is considerable interest in using targetedtherapies to broaden the clinical response to ICB.